银谷制药觅得新买方 羚锐制药超7亿元收购其90%股权

Core Viewpoint - The company, Lingrui Pharmaceutical, plans to acquire 90% of Yingu Pharmaceutical for 704 million yuan, which will enhance its overall profitability and core competitiveness through the integration of Yingu's innovative products and capabilities [1][2]. Group 1: Acquisition Details - Lingrui Pharmaceutical will acquire 90% of Yingu Pharmaceutical for 704 million yuan, with the option to purchase the remaining 10% at a later date based on a specified earnings multiple [1]. - The overall valuation of Yingu Pharmaceutical is set at 782 million yuan, which is comparable to a previous valuation of 764 million yuan by another company, Saito Bio [2]. Group 2: Yingu Pharmaceutical's Profile - Yingu Pharmaceutical, established in 2007, is an innovative pharmaceutical company engaged in drug research, raw material synthesis, production, and sales, recognized as a national high-tech enterprise [1][2]. - Key products include the salmon calcitonin nasal spray and the first high-selectivity anticholinergic receptor antagonist nasal spray in China, indicating a strong product pipeline [2]. Group 3: Strategic Implications - The acquisition is expected to enhance Lingrui's product matrix in orthopedics and respiratory fields, particularly through the addition of high-tech nasal sprays and inhalation agents [3]. - Lingrui aims to leverage its platform, resources, and sales channels to empower Yingu Pharmaceutical for rapid growth and expansion of business scale and profitability [4].